PPARD Activation Boosts CAR T Metabolic Fitness and Suppresses Colorectal Tumors in Preclinical Models

The team used mouse colorectal cancer models and human CAR T cells engineered to overexpress PPARD, then tested them in organoids grown from patient tissue, cultured cell lines, and xenograft mice. Activating the transcription factor shifted immune cell metabolism toward fat burning, improving persistence and effector function against tumors that resist standard chemotherapy and checkpoint blockade. Results held across breast, ovarian, and melanoma models, suggesting a shared metabolic vulnerability rather than cancer-type-specific effects.

Existing CAR T therapies fail in solid tumors largely because of metabolic exhaustion in the tumor microenvironment; PPARD activation offers a route to rewire that exhaustion without new antigen targets. This builds on prior work showing PPAR agonists enhance T cell memory in chronic infection models and on metabolic profiling of colorectal cancer progression in young adults, where obesity-linked lipid signaling already correlates with poor outcomes.

The approach remains untested in humans. Next steps require GMP-scale PPARD agonists or genetic engineering vectors, followed by toxicology and Phase 1 safety trials in refractory colorectal cancer, with response-rate thresholds of at least 25 percent needed to justify larger studies.

Limitations include reliance on short-term xenograft readouts and potential off-target effects of systemic PPARD modulation in non-immune cells.